SCHEMBL6907528

SCHEMBL6907528

Oc1ccccc1-c1cccc(-c2ccccc2O)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.50
SMN1; SMN2 Q16637 4/20 0.48
MAPT P10636 3/20 0.48
CASP3 P42574 2/20 0.48
SENP8 Q96LD8 2/20 0.48
SENP7 Q9BQF6 2/20 0.48
SENP6 Q9GZR1 2/20 0.48
LMNA P02545 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
RAB9A P51151 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPK10 P53779 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
HSD17B10 Q99714 2/20 0.48
BCL2L1 Q07817 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL58204 0.98 IDO1 (0.48) IDO1SMN1; SMN2MAPTCASP3SENP8
SCHEMBL2542176 0.98 IDO1 (0.48) IDO1SMN1; SMN2MAPTCASP3SENP8
Hydrochloric Acid SCHEMBL7235410 0.93 SMN1; SMN2 (0.46) IDO1SMN1; SMN2MAPTCASP3SENP8
SCHEMBL5950612 0.91 SMN1; SMN2 (0.45) IDO1SMN1; SMN2MAPTCASP3SENP8
SCHEMBL13810760 0.89 MEN1 (0.64) IDO1SMN1; SMN2MAPTCASP3SENP8
SCHEMBL5106112 0.88 MEN1 (0.61) IDO1SMN1; SMN2MAPTCASP3SENP8
SCHEMBL4921855 0.86 KDM4E (0.67) IDO1SMN1; SMN2LMNACYP1A2RAB9A
SCHEMBL7242146 0.86 IDO1 (0.44) IDO1SMN1; SMN2MAPTCASP3SENP8
SCHEMBL21084071 0.85 CCR1 (0.58) SMN1; SMN2MAPTRAB9AKMT2AHPGD
SCHEMBL15563928 0.85 IDO1 (0.47) IDO1SMN1; SMN2MAPTCASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519131-B2 Modified metal complex and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-08-27 US disclosed
US-8519131-B2 Modified metal complex and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-08-27 US disclosed
US-20100105909-A1 MODIFIED METAL COMPLEX AND USE THEREOF SUMITTO CHEMICAL COMPANY, LIMITED (JP) 2010-04-29 US disclosed
US-20100105909-A1 MODIFIED METAL COMPLEX AND USE THEREOF SUMITTO CHEMICAL COMPANY, LIMITED (JP) 2010-04-29 US disclosed
EP-2133336-A1 MODIFIED METAL COMPLEXES AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2009-12-16 EP disclosed
US-6825296-B2 COORDINATION CATALYSTS THE UNIVERSITY OF HONG KONG (HK) 2004-11-30 US disclosed
US-20030191015-A1 Catalyst component for olefin polymerization UNIVERSITY OF HONG KONG, THE (CN) 2003-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191015-A1 Catalyst component for olefin polymerization CBR1, MSMO1, DUOX1 IDO1 651/4885SMN1; SMN2 4549/4885MAPT 4409/4885
US-20100105909-A1 MODIFIED METAL COMPLEX AND USE THEREOF TPR, MT-CO2, AP3M1 IDO1 894/4885SMN1; SMN2 3486/4885MAPT 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.